{"prompt": "['B. Braun Medical Inc.', 'OPM-G-H-1506', 'Prontosan', 'Protocol Amendment 2', 'Synopsis: Inclusion', 'Inclusion Criteria #3: At least one wound must have', 'Wound age and size', 'Criteria;', 'a surface area >105 cm\u00b2 and <1630 cm\u00b2 and it must', 'changed after discussions', 'also be present for >126 weeks', 'with the Principal', 'Section 7.1: Inclusion', 'Investigators following', 'Criteria', '3 months of no subject', 'recruitment.', 'Synopsis: Exclusion', 'Exclusion Criteria #4: Antibiotic therapy within 14', 'Clarification on the use of', 'Criteria;', 'days prior to baseline (i.e., prior to first', 'topical antibiotics.', 'administration of study treatment). Topical', 'antibiotics not applied to the wound are', 'acceptable.', 'Section 7.2: Exclusion', 'Criteria', 'Section 8.4.2: Prior', 'Any Oral or intravenous antibiotic therapy.', 'Clarification on the use of', 'and Concomitant', 'Topical antibiotics not applied to the wound are', 'topical antibiotics.', 'Medications', 'acceptable.', 'Section 13.1: Study', 'Tho-In addition to the Study Products, the Sponsor', 'Clarification of items', 'Materials', 'will also supply the following items for this study:', 'supplied by the Sponsor.', 'Appendix 2', 'To qualify for this study, the wound must be between', 'Wound age and size', '510 cm\u00b2 and 1630 cm\u00b2, inclusive.', 'changed after discussions', 'with the 3 active Principal', 'Investigators following', '3 months of no subject', 'recruitment.', '14 November 2018', 'Page 8']['B. Braun Medical Inc.', 'OPM-G-H-1506', 'Prontosan', 'Protocol Amendment 2', '1', 'SYNOPSIS', 'Title of Study:', 'A Prospective Study of Quality of Life in Patients with', 'Chronic Leg Wound(s) Treated with Prontosan\u00ae Wound', 'Irrigation Solution and Prontosan R Wound Gel', 'Protocol Number:', 'OPM-G-H-1506', 'Investigators/Study Sites:', 'Approximately 5 sites in the United States.', 'Phase of Development:', '4 (post-marketing device study)', 'Objectives:', 'Primary Objective', 'The primary objective of this study is to assess the overall', 'change in the quality of life (QoL) after 4 weeks of treatment', 'with Prontosan\u00ae Wound Irrigation Solution (Prontosan', 'solution) and Prontosan\u00ae Wound Gel (Prontosan gel) in', 'patients with chronic leg wound(s). This will be determined by', 'calculating the change from baseline in the global score of the', 'Wound-QoL questionnaire.', 'Secondary Objective', 'The secondary objective is to assess the changes in the Body,', 'Psyche, and Everyday Life subscores of the Wound-QoL', 'questionnaire after 4 weeks of treatment with Prontosan', 'solution and Prontosan gel.', 'Exploratory Objective', 'The exploratory objective is to assess the change in the', 'appearance and size of the wound(s) by direct evaluation and', 'photographic measurements after 4 weeks of treatment with', 'Prontosan solution and Prontosan gel.', 'Study Design:', 'This prospective, open-label, single-arm study will evaluate the', 'change from baseline in Wound-QoL after 4 weeks of', 'treatment with Prontosan solution and Prontosan gel in adult', 'patients with chronic leg wounds. The change in the', 'appearance and size of the wound(s) will also be evaluated.', 'Patients must be outpatients at the start of the study. Patients', 'can have no more then 2 wounds below the knee(s) The', 'Investigator or designee will apply Prontosan solution and', 'Prontosan gel to the wound(s) at clinic visits, and patients will', 'apply Prontosan solution and Prontosan gel themselves (or', 'have them applied by a caregiver) at home. Study specific', 'procedures will be performed on both wounds.', 'Week 0 (Screening) Visit', 'At the Week 0 (screening) visit, after providing informed', 'consent, patients will be screened for eligibility via', 'review/assessment of inclusion and exclusion criteria.', '14 November 2018', 'Page 9']['B. Braun Medical Inc.', 'OPM-G-H-1506', 'Prontosan', 'Protocol Amendment 2', 'Assessments will include the Wound-QoL questionnaire (to be', 'completed before any other procedure), demographics,', 'concomitant medication review, medical history, vital signs,', 'physical examination, wound history, wound assessments, and', 'wound size measurements. Clinical laboratory tests', '(hematology and serum chemistry, including glycated', 'hemoglobin [HbA1c]) will be performed if results are not', 'available from tests done within 1 month prior to screening.', 'Week 1 (Baseline) Visit', 'At 1 week 1 day after the screening visit, eligible patients', 'will be enrolled at the Week 1 (baseline) visit.', 'At this visit, inclusion/exclusion criteria and medical and', 'wound history will be confirmed, and the following', 'assessments will be performed for the wound(s): the', 'Wound-QoL questionnaire (to be completed before any other', 'procedure), concomitant medication review, wound', 'assessments, wound size measurements and photography of the', 'wound(s) prior to and after cleaning/debridement, and adverse', 'event (AE) review. The wound(s) will be treated with', 'Prontosan solution and Prontosan gel by the Investigator or', 'designee per the institutional guidelines and the Prontosan', 'Instructions for Use (IFU). Bottles of Prontosan solution and', 'Prontosan gel will be dispensed in sufficient quantity for the', \"patient's treatment regimen until the next visit (Week 2). The\", \"patient (and/or the patient's caregiver) will be trained to\", 'administer the treatment at home, and the patient (and/or the', 'caregiver) will be given a diary and trained to record the date', 'and time of each treatment and any reactions to treatment in', 'the diary. Patients (and/or caregivers) will also be instructed to', 'record the liquid level remaining after each use, and to return', 'all used bottles and any unused bottles of study treatment at the', 'next visit for product accountability.', 'Week 2', 'At the Week 2 visit, the following assessments will be', 'performed at the clinic for the wound(s) the Wound-QoL', 'questionnaire (to be completed before any other procedure),', 'patient diary review, product accountability review,', 'concomitant medication review, wound assessment, wound', 'size measurement and photography of the wound prior to and', 'after cleaning/debridement, and AE review. The wound(s) will', 'be treated with Prontosan solution and Prontosan gel by the', 'Investigator or designee per the institutional guidelines and the', 'Prontosan IFU. Bottles of Prontosan solution and Prontosan', \"gel will be dispensed in sufficient quantity for the patient's\", 'treatment regimen until the next clinic visit (Week 5). The', '14 November 2018', 'Page 10']\n\n###\n\n", "completion": "END"}